14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
XBIO vs DRIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). XBIO carries a Unified Composite Score of 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin).
Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs DRIO. Trailing 12-month operating profitability (XBIO -81.0% vs DRIO -142.7%) and valuation multiples (XBIO N/M vs DRIO 10.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XBIO vs DRIO Key Questions & Quantitative Answers
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). XBIO carries a Unified Composite Score of 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin). Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DRIO leads the Growth & Scale pillar: XBIO posts +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin), compared with DRIO at +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin). On trailing 12-month operating scale, XBIO generates $3.3M in USD-normalized revenue versus $21M for DRIO. In operating R&D and SG&A reinvestment, XBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRIO.
DRIO screens cheaper on headline valuation multiples. XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin), whereas DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XBIO (-47.0% ROE) versus DRIO (-46.6% ROE) capital efficiency.
In options market volatility and institutional positioning, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 99% Vol realized risk). By comparison, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.